Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04092673
Title Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies (Zotatifin)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Effector Therapeutics

Her2-receptor positive breast cancer

Her2-receptor negative breast cancer

breast cancer

lung non-small cell carcinoma


eFT226 + Fulvestrant


eFT226 + Sotorasib

Abemaciclib + eFT226 + Fulvestrant

eFT226 + Trastuzumab

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST